title: Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.
authors: S I A
authors: SI
authors: Shah
authors: P D
authors: PD
authors: Abel
authors: R E
authors: RE
authors: Langley
authors: F H
authors: FH
authors: Cafferty
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal
references: Scand J Urol Nephrol. 2008;42(3):220-9
references: 18432528
references: N Engl J Med. 1984 Nov 15;311(20):1281-6
references: 6436700
references: J Urol. 2005 Aug;174(2):527-33; discussion 532-3
references: 16006886
references: BJU Int. 2008 Aug;102(4):442-5
references: 18422771
references: J Urol. 2004 Dec;172(6 Pt 1):2203-7
references: 15538232
references: Lancet Oncol. 2013 Apr;14(4):306-16
references: 23465742
references: Br J Cancer. 2013 Jan 15;108(1):9-13
references: 23321508
references: Urology. 1986 Jan;27(1 Suppl):21-8
references: 3079935